Literature DB >> 29339052

Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT1A receptor biased agonists.

Ivani Brys1, Pär Halje1, Robson Scheffer-Teixeira2, Mark Varney3, Adrian Newman-Tancredi3, Per Petersson4.   

Abstract

Recently, the biased and highly selective 5-HT1A agonists, NLX-112, F13714 and F15599, have been shown to alleviate dyskinesia in rodent and primate models of Parkinson's disease, while marginally interfering with antiparkinsonian effects of levodopa. To provide more detailed information on the processes underlying the alleviation of dyskinesia, we have here investigated changes in the spectral contents of local field potentials in cortico-basal ganglia-thalamic circuits following treatment with this novel group of 5-HT1A agonists or the prototypical agonist, 8-OH-DPAT. Dyskinetic symptoms were consistently associated with 80 Hz oscillations, which were efficaciously suppressed by all 5-HT1A agonists and reappeared upon co-administration of the antagonist, WAY100635. At the same time, the peak-frequency of fast 130 Hz gamma oscillations and their cross-frequency coupling to low-frequency delta oscillations were modified to a different extent by each of the 5-HT1A agonists. These findings suggest that the common antidyskinetic effects of these drugs may be chiefly attributable to a reversal of the brain state characterized by 80 Hz gamma oscillations, whereas the differential effects on fast gamma oscillations may reflect differences in pharmacological properties that might be of potential relevance for non-motor symptoms.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-OHDA rat; Dyskinesia; Local field potential; Oscillations; Parkinson's disease; Systems neurophysiology

Mesh:

Substances:

Year:  2018        PMID: 29339052     DOI: 10.1016/j.expneurol.2018.01.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  4 in total

1.  Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats.

Authors:  Adrian Newman-Tancredi; Mark A Varney; Andrew C McCreary
Journal:  Neurochem Res       Date:  2018-03-23       Impact factor: 3.996

2.  The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.

Authors:  Ria Fisher; Atsuko Hikima; Rebecca Morris; Michael J Jackson; Sarah Rose; Mark A Varney; Ronan Depoortere; Adrian Newman-Tancredi
Journal:  Neuropharmacology       Date:  2020-02-10       Impact factor: 5.250

3.  Significance and Translational Value of High-Frequency Cortico-Basal Ganglia Oscillations in Parkinson's Disease.

Authors:  Per Petersson; Pär Halje; M Angela Cenci
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

4.  6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.

Authors:  Sergio Vegas-Suárez; Clarissa Anna Pisanò; Catalina Requejo; Harkaitz Bengoetxea; Jose Vicente Lafuente; Michele Morari; Cristina Miguelez; Luisa Ugedo
Journal:  Br J Pharmacol       Date:  2020-07-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.